{"nctId":"NCT00725491","briefTitle":"A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)","startDateStruct":{"date":"2007-05"},"conditions":["Controlled Ovarian Stimulation"],"count":259,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: ganirelix"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: triptorelin"]}],"interventions":[{"name":"ganirelix","otherNames":["Orgalutran®","Org 37462"]},{"name":"triptorelin","otherNames":["Decapeptyl"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* females of infertile couples for whom COS and IVF or ICSI is indicated\n* body mass index between 18 and 29 kg/m2\n* willing and able to give written informed consent.\n\nExclusion Criteria:\n\n* More than three previous COS cycles for assisted reproduction since last established ongoing pregnancy (if applicable)\n* History of no or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment\n* Less than 2 ovaries or any other ovarian abnormality including endometrioma\n* Presence of unilateral or bilateral hydrosalpinx\n* Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound investigation of at least one ovary\n* History of or current polycystic ovary syndrome (PCOS)\n* History of/or current endocrine abnormality\n* Any clinically relevant hormone value outside the reference range during the early follicular phase\n* Any clinically significant abnormal laboratory value\n* Hypertension or currently treated hypertension\n* Recent history of current epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary disease\n* Alcohol or drug abuse, or history thereof\n* Current serious allergic symptoms\n* Abnormal cervical smear\n* Known hypersensitivity to gonadotropin releasing hormone (GnRH) or its analogs;\n* Contra-indications for the use of gonadotropins\n* Use of hormonal preparations within 1 month prior to the date of signing consent;\n* Administration of any investigational product within 3 months prior to screening.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Amount of International Units (IU) of Recombinant Follicle Stimulating Hormone (recFSH) Needed in a Controlled Ovarian Stimulation (COS) Cycle up to the First Day the Human Chorionic Gonadotropin (hCG) Criterion is Met.","description":"The hCG criterion is met the first day that 3 follicles \\>= 17 mm are observed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1272.0","spread":"265.8"},{"groupId":"OG001","value":"1415.6","spread":"355.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":112},"commonTop":["Nausea","Vomiting","Antepartum haemorrhage"]}}}